絞り込み

16761

広告

新型コロナ治療に期待「アヒガン」200万人分備蓄目指す 厚労省 (NHK)

新型インフルエンザの治療薬として政府が200万人分備蓄している「アビガン」について、厚生労働省は新型コロナウイルス感染症の治療に使う場合、1人当たりに投与する量...

  1. [企業] Menlo社のNK1受容体遮断...
  2. アルムがCOVID-19患者のCT画像の...
  3. 福島第一原発 首都圏から社員移動させず ...
  4. 厚生科学審議会 (予防接種・ワクチン分科...

ニュース一覧

Neural Predictors of the Antidepressant Placebo Response.

著者 Rette D , McDonald E , Iosifescu DV , Collins KA
Pharmaceuticals (Basel).2019 Oct 19 ; 12(4):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Full Text Sources

The antidepressant placebo response remains a barrier to the development of novel therapies for depression, despite decades of efforts to identify and methodologically address its clinical correlates. This manuscript reviews recent neuroimaging studies that aim to identify the neural signature of antidepressant placebo response. Data captured in clinical trials have primarily focused on antidepressant efficacy or predicting antidepressant response and have reliably implicated the rostral anterior cingulate cortex (rACC) in antidepressant placebo response, but also in medication response. Imaging and electroencephalography (EEG) experiments specifically interrogating the mechanism of antidepressant placebo response, while few, suggest the reward network, including opiate neurotransmission, is also involved. Therefore, while the rACC is likely involved in the antidepressant placebo response, its observation in isolation is unlikely to prospectively distinguish antidepressant placebo from medication responders. Instead, future studies of antidepressant placebo response should probe the reward network as a whole and incorporate sophisticated computational analytical approaches.
PMID: 31635043 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード